Stran & Company director granted 6,032 SWAG shares
Chippindale Alan reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chippindale Alan reported acquisition or exercise transactions in this Form 4 filing.
Stran & Company, Inc. reported that director Alan Chippindale received a grant of 6,032 shares of common stock on August 13, 2026. The grant was at a stated price of $0.00 per share, reflecting a compensation award rather than an open-market purchase. Following this award, Chippindale’s direct holdings increased to 46,373 common shares.
The award is subject to a time-based vesting schedule: it vests as to 1,508 shares on each of September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027. The filing does not indicate use of a Rule 10b5-1 trading plan for this grant.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 6,032 | $0.00 | $0.00 |
Footnotes (1)
- F1. Vests as to 1,508 shares on each of September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027.
Key Figures
Key Terms
Grant, award, or other acquisition financial
vesting schedule financial
non-derivative financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Stran & Company (SWAG) disclose about Alan Chippindale’s new stock grant?
Was Alan Chippindale’s Stran & Company (SWAG) stock transaction a market purchase or a grant?
Does the Alan Chippindale Form 4 for Stran & Company (SWAG) involve any derivative securities?
AI-generated analysis. How Rhea-AI works. Not financial advice.